Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Poole-Wilson, P.A., Lubsen, J., Kirwan, B.A., van Dalen, F.J., Wagener, G., Danchin, N., et al. (2004) A Coronary disease Trial Investigating Outcome with Nifedipine Gastrointestinal Therapeutic System Investigators. Effects of Long-Acting Nifedipine on Mortality and Cardiovascular Morbidity in Patients with Stable Angina Requiring Treatment (ACTION Trial): Randomized Controlled Trial. Lancet, 364, 849-857.
http://dx.doi.org/10.1016/S0140-6736(04)16980-8

has been cited by the following article:

  • TITLE: Review of Medical Treatment of Stable Ischemic Heart Disease

    AUTHORS: Abdulelah F. Al Mobeirek, Hanan Albackr, Mostafa Al Shamiri, Turki B. Albacker

    KEYWORDS: Medical Treatment; Stable; Ischemic Heart Disease; Novel Anti-Ischemic Therapy; Anti-Anginal Agents; Coronary Artery Disease

    JOURNAL NAME: International Journal of Clinical Medicine, Vol.5 No.5, March 21, 2014

    ABSTRACT: Medical treatment is the initial treatment strategy and is the cornerstone of management in patients with stable ischemic heart disease (IHD). Many patients are not suitable for percutaneous or surgical revascularization because of unfavourable anatomy, or the presence of co-morbidities. In addition, many patients have recurrence of angina following revascularization due to restenosis or incomplete revascularization. Furthermore, randomized clinical trials comparing optimal medical treatment to revascularization have not clearly shown that myocardial revascularization is superior to optimal medical treatment. Traditional drugs for angina treatment include b-blockers, calcium channel blockers and nitrates. Newer drugs are available with different mechanisms of action and with equal efficacy that do not cause significant hemodynamic deterioration. The availability of these newer drugs expands the therapeutic potential of medical treatment to even a wider population with stable IHD. Revascularization in patients with stable ischemic heart disease has never been shown to reduce hard endpoints (death or myocardial infarction) in randomized clinical trials.